Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker(Medical University of Vienna), U. Gatzemeier(Ontario Institute for Cancer Research), Thomas Goddemeier(Merck (Germany)), Rodryg Ramlau(Poznan University of Medical Sciences), Michael Emig(Merck (Germany)), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Keunchil Park(The University of Texas MD Anderson Cancer Center), Kenneth J. O’Byrne(Translational Research Institute), Ihor Vynnychenko(Sumy State University), Emilio Bajetta(Fondazione Lanza), Wilfried Eberhardt(National Center for Tumor Diseases), Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Chih-Teng Yu(Taoyuan Chang Gung Memorial Hospital), Jae-Kyung Roh(Yonsei University), Jose R. Pereira(Ontario Institute for Cancer Research), Filippo de Marinis(Carlo Forlanini Hospital), Aleksandra Szczęsna(Chinese University of Hong Kong), Valentyn Ganul(Institute of Urology of the National Academy of Medical Sciences of Ukraine)
Cited by 1,355
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k